A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL
Phase of Trial: Phase III
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Miltefosine (Primary)
- Indications Leishmaniasis; Visceral leishmaniasis
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2019 Status changed from recruiting to completed.
- 26 Nov 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 26 Nov 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.